GenVec | GNVC | Profile | Summary

GenVec, (GNVC) is a biopharmaceutical company using differentiated, proprietary technologies to create superior therapeutics and vaccines. A key component of the company's strategy is to develop and commercialize products through collaborations. GenVec is working with leading companies and organizations such as Novartis, Merial, and the U.S. Government to support a portfolio of product programs that address the prevention and treatment of a number of significant human and animal health concerns.

GenVec’s development programs address therapeutic areas such as hearing loss, balance disorders, and cancer; as well as vaccines against infectious diseases including respiratory syncytial virus (RSV), herpes simplex virus type 2 (HSV-2), dengue fever, influenza, malaria, and human immunodeficiency virus (HIV).

The GenVec's Advantage

The company's core technology has the important advantage of localizing protein delivery in the body. This is accomplished by using adenovector platform to locally deliver genes to cells, which then direct production of the desired protein. This approach reduces side effects typically associated with systemic delivery of proteins. For vaccines, the goal is to induce an immune response against a target protein or antigen. This is accomplished by using an adenovector to deliver a gene that causes production of an antigen, which then stimulates the desired immune reaction by the body.

GenVec’s novel proprietary adenovectors

‒

No pre existing immune recognition

‒

Built on rare human and nonhuman adenovirus serotypes

‒

New GC technology shows superior performance for genetic vaccines

‒

Multiple capsid modified vectors -AdH technology

‒

Multiple genes/multiple antigens

‒

Targeted and specific delivery Proprietary adenovectors and cell lines

‒

Novel proprietary non replicating adenovirus vectors

•

Very low sero -prevalence in humans

•

Outstanding gene/antigen delivery properties

‒

Cell line master banks and master file with FDA

Hearing Restoration Molecular Therapeutic

•

Dengue Virus Genetic Vaccine

•

Foot and Mouth Virus Genetic Vaccine

•

Malaria Genetic Vaccine

•

RSV Genetic Vaccine

•

HSV Molecular Therapeutic and Genetic Vaccine

A platform of adenovirus vectors built to meet product needs for molecular therapeutics and genetic vaccines

Don't miss the NEXT premium Alert! Sign-up, Get Alerts, MakeMoney!®

we received or expecting compensation from the featured company. Our firm, principals and staff may own/buy/sell/trade stock/securities of this company. Always Read the full Disclosure/Disclaimer. Thanks.

Disclosure/Disclaimer:- OxBridge Research publishes sponsored research reports, advertorials and corporate profiles on its portal and several other websites/blogs, including this website/blog, owned and operated by OxBridge and/or its affiliates. OxBridge Research is not a Broker Dealer or a Registered Financial Adviser in any jurisdiction, whatsoever. All the information published on its website(s) and/or distributed to its members via various electronic means is for general awareness and entertainment purpose only. OxBridge urges investors to do their own due diligence and consult with their financial adviser prior to making any investment decision. We are expecting a payment from the company/a third party/shareholder. We receive compensation from companies for providing various IR services, including publication, advertisement,and social media awareness, therefore our views/opinion are inherently biased. Please read the full disclosure/disclaimer, if you need assistance contact This e-mail address is being protected from spambots. You need JavaScript enabled to view it

OxbridgeResearch.com, All Rights Reserved. Trademarks/logos are of their respective owners.

It's YOUR money - Invest WISELY _TM